Prospective randomised study comparing luteal phase support in in-vitro fertilisation/intracytoplasmic sperm injection patients for three weeks versus seven weeks from day of positive pregnancy test
ISRCTN | ISRCTN88722916 |
---|---|
DOI | https://doi.org/10.1186/ISRCTN88722916 |
Secondary identifying numbers | N/A |
- Submission date
- 28/12/2006
- Registration date
- 25/01/2007
- Last edited
- 15/04/2008
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Pregnancy and Childbirth
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Plain English summary of protocol
Not provided at time of registration
Contact information
Prof Mohamed Aboulghar
Scientific
Scientific
3 St 161 Hadayek El Maadi
Cairo
11431
Egypt
Phone | +20 (0)25 25 49 44 |
---|---|
ghar@link.net |
Study information
Study design | A prospective randomised controlled trial |
---|---|
Primary study design | Interventional |
Secondary study design | Randomised controlled trial |
Study setting(s) | Other |
Study type | Treatment |
Scientific title | |
Study objectives | A question was sent to 18 in-vitro fertilisation (IVF) centres worldwide, asking about their policy of luteal phase support. A very wide variation in the duration of luteal phase support was noticed between different centres. The study will compare three weeks versus seven weeks of luteal phase support from day of positive beta-human chorionic gonadotropin (β-hCG) in IVF patients. |
Ethics approval(s) | Approval received from the Ethical Committee of the Egyptian IVF Center on the 15th November 2006. |
Health condition(s) or problem(s) studied | Infertility patients treated by IVF/ICSI |
Intervention | All patients receive intramuscular (IM) progesterone 50 mg daily from day of oocyte retrieval and continue for three weeks from day of positive β-hCG test, i.e. day of first ultrasound. Patients are randomised on day of first ultrasound to: Arm one: stop luteal phase support on day of first ultrasound Arm two: continue luteal phase support in the form of cyclogest (micronised progesterone 400 mg) for four more weeks. |
Intervention type | Drug |
Pharmaceutical study type(s) | |
Phase | Not Specified |
Drug / device / biological / vaccine name(s) | Progesterone |
Primary outcome measure | Miscarriage rate in the first trimester |
Secondary outcome measures | 1. Bleeding episodes in the first trimester 2. Adverse reactions to progesterone |
Overall study start date | 20/12/2006 |
Completion date | 20/06/2007 |
Eligibility
Participant type(s) | Patient |
---|---|
Age group | Adult |
Sex | Not Specified |
Target number of participants | 400 participants, 200 in each arm |
Key inclusion criteria | 1. Patients undergoing IVF/intra-cytoplasmic sperm injection (ICSI) 2. Aged less than 39 years 3. Having at least three high quality embryos |
Key exclusion criteria | Intra-cytoplasmic sperm injection (ICSI) using surgically retrieved sperm. |
Date of first enrolment | 20/12/2006 |
Date of final enrolment | 20/06/2007 |
Locations
Countries of recruitment
- Egypt
Study participating centre
3 St 161 Hadayek El Maadi
Cairo
11431
Egypt
11431
Egypt
Sponsor information
The Egyptian IVF-ET Center (Egypt)
Hospital/treatment centre
Hospital/treatment centre
3 St 161 Hadayek El Maadi
Cairo
11431
Egypt
Phone | +20 (0)25 25 49 44 |
---|---|
ivf@link.net | |
Website | http://www.egyptianivfcenter.com/ |
https://ror.org/035aahr55 |
Funders
Funder type
Other
Internally funded by the Prinicipal Investigator
No information available
Results and Publications
Intention to publish date | |
---|---|
Individual participant data (IPD) Intention to share | No |
IPD sharing plan summary | Not provided at time of registration |
Publication and dissemination plan | Not provided at time of registration |
IPD sharing plan |
Study outputs
Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
---|---|---|---|---|---|
Results article | Results | 01/04/2008 | Yes | No |